Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors
© Caenepeel et al; licensee BioMed Central Ltd. 2010
Received: 30 March 2010
Accepted: 15 July 2010
Published: 15 July 2010
Activating mutations in Kit receptor tyrosine kinase or the related platelet-derived growth factor receptor (PDGFR) play an important role in the pathogenesis of gastrointestinal stromal tumors (GIST).
This study investigated the activity of motesanib, an inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3; PDGFR; and Kit, against primary activating Kit mutants and mutants associated with secondary resistance to imatinib. Single- and double-mutant isoforms of Kit were evaluated for their sensitivity to motesanib or imatinib in autophosphorylation assays and in Ba/F3 cell proliferation assays.
Motesanib inhibited Kit autophosphorylation in CHO cell lines expressing primary activating mutations in exon 9 (AYins503-504, IC50 = 18 nM) and exon 11 (V560 D, IC50 = 5 nM; Δ552-559, IC50 = 1 nM). Motesanib also demonstrated activity against kinase domain mutations conferring imatinib resistance (V560D/V654A, IC50 = 77 nM; V560D/T670I, IC50 = 277 nM; Y823 D, IC50 = 64 nM) but failed to inhibit the imatinib-resistant D816V mutant (IC50 > 3000 nM). Motesanib suppressed the proliferation of Ba/F3 cells expressing Kit mutants with IC50 values in good agreement with those observed in the autophosphorylation assays.
In conclusion, our data suggest that motesanib possesses inhibitory activity against primary Kit mutations and some imatinib-resistant secondary mutations.
Approximately 85% to 90% of all cases of gastrointestinal stromal tumors (GIST) are associated with gain-of-function mutations in the gene KIT [1–4]. A further 5% to 10% of cases of GIST are associated with activating mutations in the platelet-derived growth factor receptor alpha (PDGFRα) gene [1, 4, 5]. Activating Kit mutations in GIST occur principally in the extracellular domain, the juxtamembrane domain (which regulates receptor dimerization), kinase domain I, and kinase domain II (or activation loop) . Imatinib, a small-molecule inhibitor of Kit and PDGFRα, represents an effective first-line therapy option for patients with advanced GIST . Imatinib is a potent inhibitor of wild-type Kit and juxtamembrane domain Kit mutants, while Kit activation loop mutants are resistant [1, 7]. Secondary imatinib resistance is most commonly associated with the acquisition of a secondary mutation in Kit (either in the kinase domain I or the activation loop) or in PDGFRα .
Motesanib is an orally administered small-molecule antagonist of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3; PDGFR and Kit [9, 10]. In clinical studies, motesanib has shown encouraging efficacy in the treatment of patients with advanced solid tumors [10–13]. In biochemical assays, motesanib potently inhibits the activity of both Kit (50% inhibitory concentration [IC50] = 8 nM) and PDGFR (IC50 = 84 nM) , suggesting that it may have direct antitumor activity in GIST [14, 15]. The aim of this study was to characterize the ability of motesanib to inhibit the activity of wild-type Kit in vitro and in vivo, and to investigate differences in the potency of motesanib and imatinib against clinically important primary activating Kit mutants and mutants associated with secondary imatinib resistance. The results suggest that motesanib has inhibitory activity against primary Kit mutations and some imatinib-resistant secondary mutations.
Unless specified otherwise all reagents were purchased from Sigma Aldrich; all cell culture reagents were purchased from Invitrogen (Carlsbad, CA).
In Vivo Hair Depigmentation Assay
Female C57B6 mice (6 to 8 weeks old; 20 to 30 g; Charles River Laboratories, Wilmington, MA) were anesthetized, and an area of skin 2 × 2 cm on the right flank was depilated. Oral administration of either 75 mg/kg motesanib (Amgen Inc., Thousand Oaks, CA) or vehicle (water, pH 2.5) was initiated on the same day as depilation and continued for 21 days. On day 21, photographs were taken for assessment of hair depigmentation. The same patch of skin was depilated again on day 28, and photographs for assessment of depigmentation were taken on day 35. All animal experimental procedures were conducted in accordance with the guidelines of the Amgen Animal Care and Use Committee and the Association for Assessment and Accreditation of Laboratory Animal Care standards.
Preparation of Wild-Type and Mutant KIT Constructs
Clinically Relevant KIT Mutations
Primary activating mutations
Secondary imatinib-refractory mutations
Juxtamembrane domain/kinase domain I
Juxtamembrane domain/kinase domain I
Stable Transfection of CHO and Ba/F3 Cells With Wild-Type and Mutant KIT
AM-1/D Chinese Hamster Ovary (CHO) cells (Amgen Inc.) were maintained under standard conditions. Cells were transfected with wild-type or mutant KIT using Lipofectamine2000 and Opti-MEM (Invitrogen) following the manufacturer's instructions. Four days after transfection, cells were transferred into selection medium: Gibco DMEM High Glucose with 10% FBS plus 300 μg/mL hygromycin (Roche Applied Sciences, Indianapolis, IN) for cells transfected with pcDNA3.1+ hygro; DMEM High Glucose with 10% dialyzed FBS for cells transfected with pDSRα22. Stably transfected CHO cells were selected 2 weeks later and maintained as described above.
Interleukin 3 (IL-3)-dependent Ba/F3 cells were maintained under standard conditions including 3 ng/mL murine IL-3 (Cat # PMC0035; Invitrogen/BioSource). Cells were transfected with wild-type or mutant KIT in the pDSRa22 expression vector along with linearized pcDNA Neo using the Nucleofector Kit V and a Nucleoporator (Lonza; Cologne, Germany) following the manufacturer's instructions. Two to 3 days post transfection, cells were transferred into selection medium (supplemented RPMI medium plus 750 μg/mL G418). Stably transfected Ba/F3 cells were maintained in supplemented RPMI medium plus 3 ng/mL murine IL-3.
Fluorescence activated cell sorting (FACS) was utilized to isolate pools of CHO and Ba/F3 cells stably expressing wild-type and mutant KIT variants. FACS was performed on a FACS Aria cell sorter (BD Biosciences San Jose, CA), under sterile conditions using 488 nm laser excitation. KIT transfected cells were labeled with the anti-Kit monoclonal antibody SR1 (prepared at Amgen Inc.; data on file) followed by incubation with FITC-labeled secondary anti-mouse IgG antibody (SouthernBiotech, Birmingham, AL). Cells were then resuspended in Dulbecco's phosphate-buffered saline with 0.5% bovine serum albumin at a final concentration of 1 × 106 cells per mL to ensure a constant and viable sorting rate of 5000 cells/sec. Cells transfected with vector control were used to adjust the baseline instrument settings. Forward and side scatter gating enabled the exclusion of dead cells and debris. The top 10% to 15% of Kit-positive cells within the overall transfected cell population were then isolated to ensure collection of high-expressing cells. Cells were sorted directly into 15 mL conical tubes containing the appropriate growth media. Cell pools were then cultured and maintained under the respective selection conditions, and were reanalyzed for Kit expression prior to characterization of Kit autophosphorylation.
Cell-Based Kit Autophosphorylation Assay
CHO cells stably transfected with wild-type or mutant isoforms of KIT were seeded in a 96-well tissue culture plate at a density of 2 × 104 cells per well. For stem cell factor (SCF) characterization experiments, cells were stimulated with serial dilutions of SCF for varying times. To determine IC50 values, the cells were treated for 2 hours with single 10-fold serial dilutions of motesanib or imatinib starting at 3 μM. Cell lines transfected with wild-type KIT were stimulated for 10 minutes with 100 ng/mL SCF following treatment with motesanib or imatinib. Cell lines transfected with activating KIT mutants were not stimulated with SCF in IC50 experiments. Cells were washed with phosphate-buffered saline and lysed in RIPA buffer (50 mM Tris, pH 7; 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 300 μM activated sodium vanadate, 1× protease inhibitor cocktail) for 30 minutes at 4°C with shaking. Cell lysates were added to a 96-well DELFIA microplate (PerkinElmer Inc.) coated with anti-Kit antibody (1 μg per well; AF332, R&D Systems, Inc.; Minneapolis, MN) and incubated for 2 hours. Lysates were then removed and the plate was washed 3 times with DELFIA wash buffer (PerkinElmer Inc.). Recombinant anti-phosphotyrosine antibody 4G10 (Cat. # 05-777; Upstate/Millipore, Billerica, MA) was added to each well (0.1 μg per well) and incubated at room temperature for 1 hour. The plate was then washed 3 times with DELFIA wash buffer before 0.01 μg of Eu-N1-labeled anti-mouse antibody (Cat. # AD0124, PerkinElmer Inc.) was added to each well. The plate was again incubated at room temperature for 1 hour and then washed 3 times with DELFIA wash buffer before the signal was detected by adding DELFIA enhancement buffer (PerkinElmer Inc.) to each well. Luminescence was measured using a Victor Model 1420 multilabel counter (PerkinElmer Inc.). Kit autophosphorylation at each motesanib or imatinib concentration was expressed as a percentage of the vehicle control (0.2% DMSO).
Ba/F3 Functional Viability Assay
The ability of Kit mutants to act as survival factors was assessed in Kit-dependent Ba/F3 cells. Ba/F3 cells stably transfected with various KIT mutants were seeded in a 96-well tissue culture plate at a density of 5 × 103 cells per well. To determine IC50 values, cells were treated for 24 hours with single 10-fold serial dilutions of motesanib or imatinib starting at 3 μM (0.1 μM for motesanib-treated V560 D and Δ552-559 Kit mutants). Cell viability was assessed by measuring the level of adenosine triphosphate using ATPlite assays (PerkinElmer Life Sciences, Boston, MA). Reconstituted ATPLite 1-step solution was added to each well followed by incubation with shaking for 2 minutes. The plate was read on a Victor Model 1420 multilabel counter (PerkinElmer Inc.) under the luminescence setting. Viability at each motesanib or imatinib concentration was expressed as a percentage of the vehicle control (0.2% DMSO).
In Vitro Inhibition of Wild-Type Kit by Motesanib
Motesanib potently inhibited SCF-induced autophosphorylation of Kit in CHO cells stably transfected with the wild-type KIT gene (IC50 = 36 nM). In comparison, imatinib inhibited wild-type Kit with an IC50 of 165 nM.
Inhibition of Wild-Type Kit Activity in Mice by Motesanib
Characterization of Kit Mutants
Activity of Motesanib against Primary Activating Kit Mutants
Inhibition of the Activity of Wild-Type Kit and Primary Activating Kit Mutants by Motesanib and Imatinib*
IC50 of Kit Autophosphorylation, nM
IC50 of Stably Transfected Ba/F3 Cell Survival, nM
Activity of Motesanib against Imatinib-Resistant Kit Mutants
Inhibition of the Activity of Kit Mutants Associated With Imatinib Resistance by Motesanib and Imatinib*
IC50 of Kit Autophosphorylation, nM
IC50 of Stably Transfected Ba/F3 Cell Survival, nM
Similarly, motesanib inhibited autophosphorylation of the imatinib-resistant activation loop mutant Y823 D (IC50 = 64 nM) more potently than imatinib (IC50 > 3000 nM) (Table 3: Figure 4B). However, neither motesanib nor imatinib inhibited autophosphorylation of the D816V mutant (Table 3). Consistent with these results, motesanib inhibited the growth of Ba/F3 cells transfected with the V560D/V654A, V560D/T670I, or Y823 D mutant more potently than imatinib. Of note, the IC50 of imatinib against the Y823 D mutant when established in the functional viability assay was at least 10-fold lower than the IC50 measured in the autophosphorylation assay. IL-3-independent Ba/F3 cells expressing the D816V Kit mutant could not be established.
In this study, motesanib was found to be a potent inhibitor of wild-type Kit, both in vitro and in vivo. In a surrogate marker assay, we observed reversible hair depigmentation in mice treated with motesanib 75 mg/kg twice daily. This dose is comparable to the doses used in xenograft studies demonstrating antitumor and antiangiogenic properties of motesanib [9, 17]. Kit signaling plays an important role in the regulation of hair follicle melanocytes, likely through control of tyrosinase and tyrosinase-related protein 1 (TRP1) expression . Depigmentation has previously been observed in mice treated with anti-Kit antibodies [16, 18] or with sunitinib . Importantly, motesanib had inhibitory activity against Kit mutants associated with GIST and inhibited these mutants more potently than imatinib and generally with an IC50 that was less than or similar to the 24-hour trough concentration of motesanib at therapeutic doses in humans .
Motesanib was a more potent inhibitor of the primary activating juxtamembrane domain and extracellular domain Kit mutants V560 D, Δ552-559, and AYins503-504, compared with imatinib. Importantly, motesanib also inhibited the activity of an activation loop mutant (Y823D) associated with imatinib resistance. Imatinib did not inhibit this mutant at concentrations of up to 3000 nM, suggesting that there are marked differences in how the two inhibitors interact with Kit. We previously solved the structure of motesanib bound to the VEGFR2 kinase domain at 2.2 Å resolution (PDB Accession Code 3EFL) . This structure superimposes favorably with that of Kit co-crystallized with imatinib (PDB Accession Code 1T46) . Both inhibitors bind the inactive, auto-inhibited form of the kinases with the backbone of the protein reorganized into the so-called "DFG-out" conformation. Based on the structural similarities and the similar potencies of motesanib against VEGFR2 and Kit, we reasoned that motesanib binds these target kinases in exactly the same fashion.
Motesanib and imatinib have much diminished activity against the activation loop mutant (D816V). The D816V mutant destabilizes the inactivated form of Kit, in a way that the ability of the protein to adopt the "DFG out" (inactive) conformation is much reduced or even eliminated; thus, the mutation prevents both motesanib and imatinib from binding to the ATP pocket [23, 24]. The failure to potently inhibit the D816V mutation is a feature of Kit inhibitors in the clinic, with the exception for dasatinib [23, 25, 26], which binds the "DFG in", or activated form, of the kinase . However, the ability of motesanib to inhibit the Y823 D mutant suggests that its activity may not be entirely restricted to an inactive protein conformation, or alternatively it may reflect that in contrast to the D816V mutation, the conformational equilibrium of the Y823 D mutant is not shifted permanently to the active conformation.
The data from the present study are of translational relevance, supporting evidence indicating that targeted therapy molecules with different binding sites and/or mode of action may be required in the treatment of cancers for which mutations are the primary oncogenic event. A recent study has demonstrated that differences in the conformational structure of Kit mutants influences the ability of sunitinib , and imatinib to bind and inhibit receptor autophosphorylation, thus providing a unique mechanism of drug resistance for each mutant that is unlikely to be overcome using a single treatment .
In summary, the results of this study demonstrate that different Kit mutations respond differently to motesanib or imatinib. This likely reflects differences in the molecules' mode of action. The data also show that motesanib is active against Kit mutations associated with resistance, suggesting that it may have clinical utility in the treatment of patients with primary and secondary imatinib-resistant GIST.
The authors wish to acknowledge Douglas Whittington and Joseph Kim (Amgen Inc., Cambridge, MA) for generating the model of motesanib bound to Kit. Additionally, the authors would like to thank Ali Hassan, PhD (Complete Healthcare Communications, Inc.), whose work was funded by Amgen Inc., and Beate Quednau, PhD (Amgen Inc.), for their assistance in the preparation of this manuscript.
- Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003, 21: 4342-4349. 10.1200/JCO.2003.04.190.View ArticleGoogle Scholar
- Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279: 577-580. 10.1126/science.279.5350.577.View ArticleGoogle Scholar
- Corless CL, McGreevey L, Haley A, Town A, Heinrich MC: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002, 160: 1567-1572.View ArticleGoogle Scholar
- Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004, 22: 3813-3825. 10.1200/JCO.2004.05.140.View ArticleGoogle Scholar
- Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA: PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003, 299: 708-710. 10.1126/science.1079666.View ArticleGoogle Scholar
- Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347: 472-480. 10.1056/NEJMoa020461.View ArticleGoogle Scholar
- Frost MJ, Ferrao PT, Hughes TP, Ashman LK: Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002, 1: 1115-1124.Google Scholar
- Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006, 24: 4764-4774. 10.1200/JCO.2006.06.2265.View ArticleGoogle Scholar
- Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006, 66: 8715-8721. 10.1158/0008-5472.CAN-05-4665.View ArticleGoogle Scholar
- Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007, 25: 2369-2376. 10.1200/JCO.2006.07.8170.View ArticleGoogle Scholar
- Price TJ, Lipton L, McGreivy J, McCoy S, Sun YN, Rosenthal MA: Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br J Cancer. 2008, 99: 1387-1394. 10.1038/sj.bjc.6604723.View ArticleGoogle Scholar
- Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009, 27: 3794-3801. 10.1200/JCO.2008.18.7815.View ArticleGoogle Scholar
- Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ: Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008, 359: 31-42. 10.1056/NEJMoa075853.View ArticleGoogle Scholar
- Benjamin R, Schöffski P, Hartmann JT, Bui BN, Duyster J, Schuetze S, Blay J, Reichard P, Rosen L, Skubitz K, Eschenberg M, Stepan D, Baker L: Initial results of a multicenter single arm phase 2 study of AMG 706, an oral multi-kinase inhibitor, for the treatment of advanced imatinib-resistant gastrointestinal stromal tumors (GIST) [abstract 641]. Connective Tissue Oncology Society 12th Annual Meeting. 2006, Venice, Italy. YearGoogle Scholar
- Sawaki A, Yamada Y, Komatsu Y, Kanda T, Doi T, Koseki M, Baba H, Sun YN, Murakami K, Nishida T: Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer Chemother Pharmacol. 2009, 65: 961-967. 10.1007/s00280-009-1103-9.View ArticleGoogle Scholar
- Botchkareva NV, Khlgatian M, Longley BJ, Botchkarev VA, Gilchrest BA: SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J. 2001, 15: 645-658. 10.1096/fj.00-0368com.View ArticleGoogle Scholar
- Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A: Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res. 2009, 15: 110-118. 10.1158/1078-0432.CCR-08-1155.View ArticleGoogle Scholar
- Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD: Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther. 2003, 307: 476-480. 10.1124/jpet.103.052530.View ArticleGoogle Scholar
- Tasker AS, Patel VF: Discovery of motesanib. Kinase Inhibitor Drugs. Edited by: Li R, Stafford JA. 2009, Hoboken, NJ: John Wiley & Sons, Inc., 113-130. full_text.View ArticleGoogle Scholar
- Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 2004, 279: 31655-31663. 10.1074/jbc.M403319200.View ArticleGoogle Scholar
- McLean SR, Gana-Weisz M, Hartzoulakis B, Frow R, Whelan J, Selwood D, Boshoff C: Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther. 2005, 4: 2008-2015. 10.1158/1535-7163.MCT-05-0070.View ArticleGoogle Scholar
- Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, Ashman LK: Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther. 2007, 6: 1159-1166. 10.1158/1535-7163.MCT-06-0641.View ArticleGoogle Scholar
- Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, Dinitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD: KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA. 2009, 106: 1542-1547. 10.1073/pnas.0812413106.View ArticleGoogle Scholar
- Foster R, Griffith R, Ferrao P, Ashman L: Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model. 2004, 23: 139-152. 10.1016/j.jmgm.2004.04.003.View ArticleGoogle Scholar
- Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006, 66: 473-481. 10.1158/0008-5472.CAN-05-2050.View ArticleGoogle Scholar
- Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006, 108: 286-291. 10.1182/blood-2005-10-3969.View ArticleGoogle Scholar
- Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE: The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006, 66: 5790-5797. 10.1158/0008-5472.CAN-05-4187.View ArticleGoogle Scholar
- Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368: 1329-1338. 10.1016/S0140-6736(06)69446-4.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.